NCT02185131View on ClinicalTrials.gov

Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Major Depressive DisorderAlcohol Use Disorder
Interventions
DRUG

Mirtazapine

Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.

DRUG

Placebo

Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.

Trial Locations (1)

15213

Western Psychiatric Institute and Clinic, Pittsburgh

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

University of Pittsburgh

OTHER

NCT02185131 - Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD. | Biotech Hunter | Biotech Hunter